Imugene Ltd has released a press release.
Complete Response in MAST Study Maintained Over Two Years
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene Receives Orphan Drug Designation for VAXINIA
- Three Complete Responses in Azer-Cel Phase 1b Trial
- First patient dosed in Phase 1 bile tract cancer trial
- Imugene onCARlytics Doses First Patient in IV Combination
- Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
Later from Imugene
- Imugene Opens First Australian Site for azer-cel Trial
- onCARlytics Trial Doses First Patient in IT Combination Arm
- Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
- Issuance of Convertible Notes & Warrants for up to $46m
- First Australian Patient Dosed in Phase 1b azer-cel Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene